REG - Cambridge Cognition - Block Listing Return

Cambridge Cognition HoldingsAnnouncement

01/04/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250401:nRSA0174Da&default-theme=true

RNS Number : 0174D  Cambridge Cognition Holdings PLC  01 April 2025

1 April 2025

 

Cambridge Cognition Holdings plc

 

("Cambridge Cognition", the "Company" or the "Group")

 

Block Listing Return

 

The Company makes the following notification pursuant to AIM Rule 29 and
Schedule Six of the AIM Rules for Companies, regarding its existing block
listings:

 

 

 Name of applicant:                                                                Cambridge Cognition Holdings plc
 Name of scheme:                                                                   Share Options
 Period of return:                        From:                                    1 October 2024               To:                          31 March 2025
 Number and class of share(s) (amount of stock / debt securities) originally       1,000,000 ordinary shares of £0.01 each in the Company admitted to trading on
 listed and the date of admission:                                                 23 March 2023
 Balance of unallotted securities under scheme(s) from previous return:            466,316 ordinary shares
 Plus:  The amount by which the block scheme(s) has been increased since the       Nil
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:        Nil
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        466,316 ordinary shares

 

 Name of contact:              Simon McKeating
 Telephone number of contact:  +44 (0)1223 810700

 

 

Enquiries:

 

 Cambridge Cognition Holdings plc                                 Tel: 012 2381 0700

 Rob Baker, Joint Managing Director and Chief Operating Officer   press@camcog.com (mailto:press@camcog.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)                 Tel: 020 7886 2968

 Freddy Crossley / Will Goode / Mark Rogers                       (Corporate Finance)

 Rupert Dearden                                                   (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                           Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                             Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus / Harry Griffiths                 cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital
health products that advance brain health research and treatment.

The company offers four core products: CANTAB® assessments-providing
scientifically validated, highly sensitive, precise, and objective measures of
cognitive function correlated to neural networks; a flexible and proven eCOA
platform with an extensive library of instruments, enabling efficient study
setup and scalable data capture; rater training services that standardise
assessment delivery and scoring across clinical trials and quality assurance
tools that ensure data integrity by automatically detecting deviations in
administration and scoring, saving time and money. These products collectively
improve clinical trial outcomes, enable early patient identification, and
enhance global efficiency in healthcare and pharmaceuticals.

For further information, visit: www.cambridgecognition.com
(https://eur01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.cambridgecognition.com%2F&data=05%7C02%7Chgriffiths%40hudsonsandler.com%7Cc696c6a3150d40f91a9508dcfdd13b58%7Ca33bdb157e25438ab1fd5c523a8866f9%7C0%7C0%7C638664322305026349%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=vQVOIVxNQ8WYYOufDnSVKUH0oa7PLvXjnP0VT%2FzCfJc%3D&reserved=0)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLREAXDFDAESEFA